GT
AH

Glenmede Trust’s Accretive Health AH Stock Holding History

Glenmede Trust’s Portfolio AH Stock Details AH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-4,000
Closed -$36K – 2444
2013
Q4 		$36K Hold
4,000
– – ﹤0.01% 1703
2013
Q3 		$36K Hold
4,000
– – ﹤0.01% 1665
2013
Q2 		$43K Buy
+4,000
New +$42.1K ﹤0.01% 1557

Other funds holding AH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JRP
Jasper Ridge Partners Menlo Park, California $4.69B AUM 31.34% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

Glenmede Trust's AH Position: Q1 2014 in Review

Glenmede Trust sold out of Accretive Health (AH) in Q1 2014, closing a stake of 4,000 shares — an estimated $36K sold.

Glenmede Trust first reported a position in AH in Q2 2013 and held it in 3 quarters. The position peaked at $43K in Q2 2013. 66 funds tracked by Wall St. Rank hold AH as of Q1 2014.

  • Glenmede Trust reported no remaining Accretive Health position as of Q1 2014 after selling out during the quarter.
  • Glenmede Trust sold 4,000 Accretive Health shares in Q1 2014, an estimated $36K.
  • Glenmede Trust first reported a position in Accretive Health in Q2 2013 and held it in 3 quarters.
  • Glenmede Trust's Accretive Health position peaked at $43K in Q2 2013.
  • 66 funds tracked by Wall St. Rank held Accretive Health as of Q1 2014.

Based on Glenmede Trust's 13F filing for Q1 2014, filed 7 May 2014.